Plus, news about Novartis, CombiGene, ProQR and Aardvark Therapeutics:
Biogen presents full Phase 2 data for felzartamab: The drug, which was acquired in Biogen’s $1.15 billion buyout of HI-Bio earlier this year, showed patients with ...
↧